---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-008894"
form_type: "8-K"
ticker: "GANX"
cik: "0001819411"
company_name: "Gain Therapeutics, Inc."
filed_at: "2024-01-31T23:59:59+00:00"
generated_at: "2026-06-06T13:59:32.523201+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Gain Therapeutics CEO provides operational update; Phase 1 trial advancing, cash runway into 2025

## Summary
- Phase 1 SAD/MAD trial of GT-02287 underway; MAD cohort expected to start Q1 2024, completion by mid-2024.
- $10.1M gross proceeds from Nov 2023 CMPO/PIPE financing; cash runway into 2025 to fund biomarker proof-of-concept.
- Computational platform renamed Magellan, now integrates AI/ML and screens 50B+ chemical compounds.
- CTO Dr. Xavi Barril leaving; company searching for Chief Medical Officer for clinical development.
- Anticipated milestones: MAD completion, Parkinson's patient cohort Q3 2024, biomarker data late 2024/early 2025.

## SEC filing metadata
- accession: 0001104659-24-008894
- form_type: 8-K
- ticker: GANX
- cik: 0001819411
- company_name: Gain Therapeutics, Inc.
- filed_at: 2024-01-31T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1819411/000110465924008894/0001104659-24-008894-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1819411/000110465924008894/tm244785d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-008894
- JSON: https://secwatch.observer/filing/0001104659-24-008894.json
- Plain text: https://secwatch.observer/filing/0001104659-24-008894.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.